WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: a phase 2, randomized, double blind, placebo controlled study.
Cutaneous leishmaniasis (cl) is a disfiguring disease that confronts clinicians with a quandary: leave patients untreated or engage in a complex or toxic treatment. Topical treatment of CL offers a practical and safe option. Accordingly, the treatment of CL with WR279,396, a formulation of paromomyc...
Main Authors: | Afif Ben Salah, Pierre A Buffet, Gloria Morizot, Nathalie Ben Massoud, Amor Zâatour, Nissaf Ben Alaya, Nabil Bel Haj Hamida, Zaher El Ahmadi, Matthew T Downs, Philip L Smith, Koussay Dellagi, Max Grögl |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2009-01-01
|
Series: | PLoS Neglected Tropical Diseases |
Online Access: | http://europepmc.org/articles/PMC2673687?pdf=render |
Similar Items
-
Parasite load decrease during application of a safe and easily applied antileishmanial aminoglycoside cream.
by: Afif Ben Salah, et al.
Published: (2014-05-01) -
A prospective cohort study of Cutaneous Leishmaniasis due to Leishmania major: Dynamics of the Leishmanin skin test and its predictive value for protection against infection and disease.
by: Jihène Bettaieb, et al.
Published: (2020-08-01) -
Temporal dynamics and impact of climate factors on the incidence of zoonotic cutaneous leishmaniasis in central Tunisia.
by: Amine Toumi, et al.
Published: (2012-01-01) -
Immunity Against Leishmania major Infection: Parasite-Specific Granzyme B Induction as a Correlate of Protection
by: Thouraya Boussoffara, et al.
Published: (2018-11-01) -
Antiretroviral activity of aminothiols, WR2721 and WR1065
by: Walker Dale M, et al.
Published: (2006-12-01)